On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Orthopedic non-invasive stem cell therapy regenerates damaged tissue rather than just improving symptoms. Autologous stem cell therapy uses cells from your own body, minimizing rejection risks.

First-in-human data now includes five patients, with follow-up ranging from 23 weeks to over a year post-treatment Injections of Wnt-activated, autologous, expanded, adipose-derived stem cells ...

NEWPORT BEACH, CA, UNITED STATES, August 25, 2025 / EINPresswire.com / -- Regeneration Biomedical, Inc. (RBI), a pioneering biotechnology company developing stem cell therapies for neurodegenerative ...

Addressing the need for alternative approaches to the treatment of Alzheimer's disease, RBI takes a different route - direct injection into the brain. With the completion of this Phase 1, RBI advances ...

Stem cell transplants remain essential for blood cancers, with expanded donor options including half-matched family members and umbilical cord blood. Cyclophosphamide has improved graft-versus-host ...

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson’s disease in which a patient’s stem ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...